These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 28717941)

  • 21. Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.
    Armstrong N; Joore M; van Asselt T; Misso K; Manning N; Tomini F; Kleijnen J; Riemsma R
    Pharmacoeconomics; 2013 May; 31(5):415-25. PubMed ID: 23580355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data.
    Üsküdar Cansu D; Üsküdar Teke H; Temel T; Ertürk A; Kahraman O; Korkmaz C
    J Natl Med Assoc; 2019 Jun; 111(3):262-269. PubMed ID: 30389147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials.
    Zhang Z; Fan W; Yang G; Xu Z; Wang J; Cheng Q; Yu M
    BMJ Open; 2017 Mar; 7(3):e012567. PubMed ID: 28336735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
    Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
    Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation.
    Corbett M; Soares M; Jhuti G; Rice S; Spackman E; Sideris E; Moe-Byrne T; Fox D; Marzo-Ortega H; Kay L; Woolacott N; Palmer S
    Health Technol Assess; 2016 Feb; 20(9):1-334, v-vi. PubMed ID: 26847392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance of ultrasound to monitor Achilles enthesitis in patients with ankylosing spondylitis during TNF-a antagonist therapy.
    Wang CH; Feng Y; Ren Z; Yang X; Jia JF; Rong MY; Li XY; Wu ZB
    Clin Rheumatol; 2015 Jun; 34(6):1073-8. PubMed ID: 25896532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.
    Dommasch ED; Abuabara K; Shin DB; Nguyen J; Troxel AB; Gelfand JM
    J Am Acad Dermatol; 2011 Jun; 64(6):1035-50. PubMed ID: 21315483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis.
    Baji P; Péntek M; Szántó S; Géher P; Gulácsi L; Balogh O; Brodszky V
    Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S45-52. PubMed ID: 24832835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis.
    Murdaca G; Negrini S; Magnani O; Penza E; Pellecchio M; Gulli R; Mandich P; Puppo F
    Mod Rheumatol; 2018 May; 28(3):417-431. PubMed ID: 28837372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
    Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
    Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.
    Fafá BP; Louzada-Junior P; Titton DC; Zandonade E; Ranza R; Laurindo I; Peçanha P; Ranzolin A; Hayata AL; Duarte A; Silveira IG; Costa I; Macieira JC; Guedes-Barbosa LS; Bertolo MB; Sauma MF; Silva MB; Freire M; Scheinberg MA; Fernandes V; Bianchi W; Miranda JR; Pinheiro GR; Carvalho HM; Brenol CV; Pereira IA; de Castro GR; de Morais JC; Oliveira SK; de Abreu MM; Toledo RA; Pinheiro MM; Vieira WP; Valim V;
    Clin Rheumatol; 2015 May; 34(5):921-7. PubMed ID: 25851594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Biologics in the early treatment of ankylosing spondylitis and related forms of spondyloarthritis].
    Langer HE
    Wien Med Wochenschr; 2008; 158(7-8):200-5. PubMed ID: 18500471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis.
    Wang R; Dasgupta A; Ward MM
    J Rheumatol; 2018 Apr; 45(4):481-490. PubMed ID: 29335342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis.
    van der Heijde D; Zack D; Wajdula J; Sridharan S; Koenig AS
    Scand J Rheumatol; 2014; 43(1):49-53. PubMed ID: 24182312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.
    Escudero-Vilaplana V; Ramírez-Herráiz E; Alañón-Plaza E; Trovato-López N; García-Vicuña R; Carreño-Pérez L; Morell-Baladrón A; Sanjurjo-Sáez M
    Int J Clin Pharm; 2015 Oct; 37(5):808-14. PubMed ID: 25910480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.